Published in Surgery on June 05, 2008
Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clin Cancer Res (2014) 2.04
Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci (2012) 1.32
Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta (2011) 1.17
Chronic inflammation in cancer development. Front Immunol (2012) 1.14
Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS One (2012) 1.10
Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (2013) 1.09
The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol (2012) 1.05
Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol (2011) 1.01
M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer (2015) 1.01
Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. PLoS One (2013) 0.99
Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Curr Pharm Des (2012) 0.98
Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm Res (2010) 0.96
Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Biochim Biophys Acta (2013) 0.96
Viable but not culturable forms of Legionella pneumophila generated after heat shock treatment are infectious for macrophage-like and alveolar epithelial cells after resuscitation on Acanthamoeba polyphaga. Microb Ecol (2014) 0.89
Epidermal growth factor (EGF) and interleukin (IL)-1β synergistically promote ERK1/2-mediated invasive breast ductal cancer cell migration and invasion. Mol Cancer (2012) 0.87
Oxidative stress and cytokines in the pathogenesis of pancreatic cancer. J Cancer Prev (2014) 0.82
Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA. Nanomedicine (2015) 0.76
Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism. Surgery (2017) 0.75
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther (2007) 3.61
Prostaglandins and cancer. Gut (2005) 3.44
The IL-1 family and inflammatory diseases. Clin Exp Rheumatol (2004) 3.10
Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell (2003) 3.03
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res (1999) 3.00
The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev (2006) 2.74
Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol (2006) 2.66
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer (2006) 2.57
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch (2003) 2.53
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol (2006) 2.51
Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim Biophys Acta (2002) 2.26
Characterization of a human macrophage-like cell line stimulated in vitro: a model of macrophage functions. J Immunol (1980) 2.06
Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol (2004) 1.88
Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol (1998) 1.66
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res (2005) 1.57
Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res (2007) 1.52
Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res (1989) 1.43
Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas (2003) 1.40
Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer (2001) 1.39
Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov (2004) 1.38
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res (2006) 1.23
PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun (2003) 1.22
Retracted In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer (2007) 1.19
Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med (2003) 1.19
Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res (2005) 1.17
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol (2006) 1.14
The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res (2005) 1.14
Induction of COX-2 and PGE(2) biosynthesis by IL-1beta is mediated by PKC and mitogen-activated protein kinases in murine astrocytes. Br J Pharmacol (2000) 1.13
Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clin Exp Metastasis (2004) 1.05
Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res (2003) 1.05
Tangeretin suppresses IL-1beta-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells. Biochem Pharmacol (2006) 0.98
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab (2005) 0.96
Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases. Oncogene (2006) 0.93
Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene (2006) 0.92
The recruitment of the interleukin-1 (IL-1) receptor-associated kinase (IRAK) into focal adhesion complexes is required for IL-1beta -induced ERK activation. J Biol Chem (2000) 0.91
Interleukin-1beta induces cyclo-oxygenase-2 expression in gastric cancer cells by the p38 and p44/42 mitogen-activated protein kinase signaling pathways. J Gastroenterol Hepatol (2001) 0.89
Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res (2004) 0.88
Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol Invest (2006) 0.86
Time dependent production of cytokines and eicosanoids by human monocytic leukaemia U937 cells; effects of glucocorticosteroids. Mediators Inflamm (1999) 0.86
Promoter analysis of human CC chemokine CCL23 gene in U937 monocytoid cells. Biochim Biophys Acta (2007) 0.83
Involvement of PKC, p38 MAPK and AP-2 in IL-1beta-induced expression of cyclooxygenase-2 in human pulmonary epithelial cells. Respirology (2006) 0.80
Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy. Int J Mol Med (2003) 0.79
Typing of leukocytes in pancreatic tissue surrounding human pancreatic carcinoma. Ann N Y Acad Sci (1999) 0.78
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res (2009) 2.36
Pancreatic-pleural fistula is best managed by early operative intervention. Surgery (2009) 2.03
Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol (2008) 1.82
Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol (2010) 1.82
Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg (2008) 1.73
Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis. Gastrointest Endosc (2004) 1.70
Laparoscopic surgery for cancer: a systematic review and a way forward. J Am Coll Surg (2010) 1.58
Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem (2006) 1.58
Controversies in clinical pancreatology: management of acute idiopathic recurrent pancreatitis. Pancreas (2003) 1.56
Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol (2009) 1.53
Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res (2007) 1.52
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. J Gastrointest Surg (2009) 1.47
Management of pancreatic fistulas after pancreaticoduodenectomy: results in 437 consecutive patients. Arch Surg (2005) 1.47
Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett (2006) 1.41
Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas (2003) 1.40
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer (2003) 1.39
Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer (2002) 1.39
Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res (2005) 1.38
Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem (2013) 1.37
Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg (2006) 1.36
Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS One (2009) 1.35
Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg (2007) 1.34
Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery (2011) 1.32
Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol (2008) 1.32
Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg (2003) 1.30
Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg (2007) 1.25
Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas (2005) 1.25
Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol (2012) 1.23
PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun (2003) 1.22
Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg (2008) 1.21
The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology (2011) 1.19
Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta (2011) 1.17
Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res (2005) 1.17
The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res (2005) 1.14
Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas (2008) 1.12
A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer. Pancreas (2005) 1.12
Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol (2011) 1.11
The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer (2006) 1.11
The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg (2005) 1.11
High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila) (2013) 1.08
Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res (2004) 1.07
VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg (2002) 1.07
Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Pancreas (2008) 1.06
Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clin Exp Metastasis (2004) 1.05
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia (2009) 1.05
Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas (2013) 1.05
Human cytokine levels in nonperforated versus perforated appendicitis: molecular serum markers for extent of disease? Am Surg (2002) 1.05
VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery (2005) 1.04
The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas (2003) 1.02
An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas (2003) 1.01
Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol (2009) 1.00
Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer (2010) 1.00
Surgical treatment of chronic pancreatitis. J Hepatobiliary Pancreat Surg (2002) 0.98
Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res (2006) 0.97
Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid. Pancreas (2003) 0.97
Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia (2007) 0.96
Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Biochim Biophys Acta (2013) 0.96